Biotech Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Cancer Vaccine

CpG ODNs induce immunity against a TERT-derived modified cryptic MHC class I-restricted epitope

According to recent research from France, "The use of synthetic peptides derived from tumor-associated antigens is attractive for the development of antitumoral vaccines as far as strong adjuvants are found to render them immunogenic. We investigated the possibility to enhance the CD8 response against the human and mouse shared TERT_572y HLA-A*0201 restricted modified cryptic peptide by using ODN-CpG as adjuvant."

"Humanized transgenic mice were...

• View Other Issues of Biotech Business Week
  
• View Other NewsRx Publications